Cara Therapeutics, Inc. Company Profile

23:17 EST 20th January 2017 | BioPortfolio

News Articles [1945 Associated News Articles listed on BioPortfolio]

Cara Therapeutics Inc: The CARA Stock Chart Says It All

CARA Stock: Bullish Tailwinds Cara Therapeutics Inc (NASDAQ:CARA) stock has caught my an eye for a number of reasons. The price chart is compelling and constructive, and the company is delving into...

BRIEF-Cara Therapeutics reports Q3 loss per share $0.42

* Cara therapeutics inc- top line data expected in 1h 2017 from three late-stage clinical programs

BRIEF-Cara therapeutics posts Q2 shr loss $0.48

* Cara therapeutics reports second quarter 2016 financial results

Cara Therapeutics' (CARA) CEO Derek Chalmers on Q3 2016 Results - Earnings Call Transcript

Cara Therapeutics' (CARA) CEO Derek Chalmers on Q2 2016 Results - Earnings Call Transcript

Cara Therapeutics (CARA) presents at JP Morgan Healthcare Conference

Enteris BioPharma's Feasibility to Licensing Partner, Cara Therapeutics, Advances ...

Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, commented, "We congratulate Cara Therapeutics on the initiation of its Phase 2b clinical Read more...

BRIEF-Cara Therapeutics starts enrollment in phase 2B trial of oral CR845

* Cara Therapeutics initiates enrollment in phase 2B trial of peripherally acting kappa opioid agonist, oral CR845, in chronic pain patients

Clinical Trials [20 Associated Clinical Trials listed on BioPortfolio]

Metabolomic Approach to Evaluate the Effect of Orange Juice Intake in Healthy Humans (METABORANGE).

This study evaluates the effect of intake of two orange juice varieties in healthy adults. The participants will receive "Bahia" orange juice, "Cara-Cara" orange juice or a isocaloric cont...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Beat AML Core Study

In this study, DNA sequencing, computational biology modeling, and ex vivo drug sensitivity assays will be utilized to define clinically relevant gene mutations and identify potential ther...

Localized Therapeutics for the Treatment of Gastrointestinal Disorders II

The purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.

Amnis Therapeutics Thrombectomy Device-First in Man (FIM) Safety and Performance Study

Prospective, single-arm, open label, Safety and Performance clinical investigation.

Companies [10 Associated Companies listed on BioPortfolio]

CARA Therapeutics

Cara possesses both near-term clinical development opportunities, combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's first patented compound, CR665, has enter...

Antegrin Therapeutics, Inc.

Antegrin Therapeutics, Inc., is a pharmaceutical company dedicated to developing novel treatments for fibrotic diseases. The company aims to select its first clinical development ...

Constance Therapeutics

Constance Therapeutics is a vertically integrated medicinal cannabis company producing standardized and science-based whole plant cannabis extracts. The company has created a new ...

Cara Therapeutics, Inc.


More Information about "Cara Therapeutics, Inc." on BioPortfolio

We have published hundreds of Cara Therapeutics, Inc. news stories on BioPortfolio along with dozens of Cara Therapeutics, Inc. Clinical Trials and PubMed Articles about Cara Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cara Therapeutics, Inc. Companies in our database. You can also find out about relevant Cara Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record